ClinicalTrials.gg
RecruitingNCT06517875ODYSSEYUpdated Nov 4, 2026

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

A Phase 2 interventional study of Momelotinib and Luspatercept in Primary Myelofibrosis and Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, sponsored by GlaxoSmithKline. Recruiting at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Updated Nov 4, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing momelotinib in Primary Myelofibrosis — 3 open to participants now, 4 under way, none of them phase 3. momelotinib · Primary Myelofibrosis.

Planned enrollment
9th of 12
68 · median 138
Started
2025
the only one that year
Phase 2
5 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
2 of 12
GlaxoSmithKline

Among the 12 studies testing momelotinib in Primary Myelofibrosis, this one is the 9th largest by planned enrollment, is the only one that started in 2025, is one of 5 in phase 2, and was the 10th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 12 studies testing momelotinib in Primary Myelofibrosis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About momelotinib

momelotinib: first FDA approval 2023 (OJJAARA), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing momelotinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.

03

Conditions studied

  • Primary Myelofibrosis
  • Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

Browse trials for

Keywords

  • Momelotinib; Luspatercept; Primary Myelofibrosis; Secondary Myelofibrosis; JAK inhibitor; anemia transfusion; Ojjara; Omjjara; Reblozyl
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is age ≥18 years.
  2. Confirmed diagnosis of PMF in accordance with the World Health Organization (WHO) 2016 criteria, or Post-PV/ET myelofibrosis in accordance with the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria.
  3. JAKi naïve or previously treated with either ruxolitinib or fedratinib for PMF or Post-PV/ET myelofibrosis for ≥90 days, or ≥28 days if JAKi therapy is complicated by RBC transfusion requirement of ≥4 units in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma.
  4. High risk, intermediate-2, or intermediate-1 risk as defined by Dynamic International Prognostic Scoring System (DIPSS) [Passamonti, 2010] or DIPSS-plus [Gangat, 2011].
  5. TD defined as requiring RBC transfusion ≥4 units or HgB \< 8 g/dL in the 8 weeks prior to the first dose of study treatment (NOTE: 2 consecutive \< 8 g/dL, at least 1 week apart are required; Hgb values impacted by transfusions are excluded). Only transfusions given when Hgb levels are ≤9.5 g/dL are counted towards TD. RBC transfusions given for clinically overt bleeding, or accident/injury (as assessed by the investigator) are not counted towards TD.

Exclusion criteria

Exclusion Criteria:

  1. History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (e.g., uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study intervention or result in inability to swallow oral medications.
  2. Participants with an invasive or history of invasive malignancy other than the disease under study within the last 5 years.
  3. Known anemia due to iron, vitamin B12, or folate deficiencies, or or hereditary hemolytic anemia, gastrointestinal bleeding, or thalassemia.
  4. Uncontrolled intercurrent illness:

    1. Active uncontrolled infection (participants receiving outpatient antibacterial and/or antiviral treatments for infection that is under control or as infection prophylaxis may be included in the trial);
    2. Significant active or chronic bleeding event ≥ Grade 2 per (CTCAE) v5.0, within 4 weeks prior to the first dose of study treatment; or
    3. Uncontrolled acute and chronic liver disease (e.g., score ≥10) OR has current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. NOTE: Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria.
  5. Uncontrolled hypertension, defined as repeated elevations of systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, that is not resolved at the time of the first dose of study treatment.
  6. Any of the following in conditions within 6 months prior to the first dose of study intervention:

    1. Unstable angina pectoris; OR
    2. Symptomatic congestive heart failure; OR
    3. Uncontrolled cardiac arrhythmia
  7. >450 msec or QTc >480 msec for participants with bundle branch block.
  8. Participants with stroke, deep venous thrombosis, pulmonary or arterial embolism within 6 months prior to the first dose of study intervention.
  9. History of porphyria.
  10. Presence of peripheral neuropathy ≥Grade 2 per CTCAE v5.0.
  11. Use of the following treatments within the time periods noted NOTE: All active anti-MF therapy must discontinue at least 1 week prior to the start of baseline MFSAF recording (Study Day -7):

    1. Active anti-MF therapy within 28 days or 5 half-lives, whichever is shorter (exception is prior JAKi therapy).
    2. use for the treatment of myelofibrosis is prohibited within 14 days prior to the first dose of study treatment until discontinuation of study treatment. Supportive care including steroids for non-myelofibrosis indications may be used.
    3. Potent cytochrome P450 3A4 () inducers, except for rifampin and rifampicin, within 14 days prior to the first dose of study intervention.
    4. Any prior agent for myelofibrosis within 4 weeks prior to the first dose of study treatment.
    5. Erythropoiesis stimulating agent (ESA) within 4 weeks prior to the first dose of study treatment.
    6. Splenic irradiation within 3 months prior to the first dose of study treatment.
  12. Prior treatment with MMB.
  13. Prior treatment with TGF-β pathway ligand traps (e.g., luspatercept or sotatercept).
  14. Prior splenectomy.
  15. Inability or unwillingness to comply with the protocol restrictions on myelofibrosis therapy and other medications prior to and during study treatment.
  16. Unresolved non-hematologic toxicities from prior therapies that are >Grade 1 per CTCAE v5.0 unless otherwise specified.
  17. Known positive status for (HIV).
  18. Hepatitis A, B, or C status as defined below:

    1. Chronic active or acute viral hepatitis A.
    2. Active infection indicated by the presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to the first dose of study intervention.
    3. Positive antibody test result at screening or within 3 months before the first dose of study intervention. NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative hepatitis C ribonucleic acid (RNA) test is obtained.
  19. Women who are already pregnant or lactating.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Momelotinib + Luspatercept

    Participants with transfusion dependent primary myelofibrosis or post- PV/ ET myelofibrosis that is JAKi naïve or JAKi experienced will receive momelotinib and luspatercept.

    Drug: Momelotinib · Drug: Luspatercept

Interventions

  • Momelotinib will be administered orally.

    Also known as: Ojjaara; CYT387

  • Luspatercept will be administered subcutaneously.

    Also known as: REBLOZYL; ACE-536

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with TI Response by Week 24

    TI response is defined as not requiring red blood cell (RBC) transfusion (except in the case of clinically overt bleeding) for any ≥12-week interval.

    Time frame: Up to Week 24

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation

    Time frame: Up to approximately 36 weeks

  2. Number of Participants with Clinically Important Changes in Laboratory Parameters, Vital Signs, and Eastern Cooperative Oncology Group (ECOG) Performance Status

    Time frame: Up to Week 24

  3. Percentage of Participants with TI at the End of Week 24

    TI was defined as not requiring RBC transfusion (except in the case of clinically overt bleeding) for ≥12 weeks preceding Week 24, with all hemoglobin (Hgb) levels during the ≥12-week interval of ≥8 g/dL (except in the case of clinically overt bleeding).

    Time frame: Up to Week 24

  4. Plasma Concentration of MMB

    Time frame: Up to Week 24

  5. Plasma Concentration of Morpholino Lactam (M21)

    Time frame: Up to Week 24

07

Study locations

33 of 33 sites recruiting
  • GSK Investigational Site
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • GSK Investigational Site
    New York, New York 10032, United States
    Recruiting
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77030, United States
    Recruiting
  • GSK Investigational Site
    Seattle, Washington 98109, United States
    Recruiting
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 1Y6, Canada
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • GSK Investigational Site
    Lyon, Rhône 69004, France
    Recruiting
  • GSK Investigational Site
    Angers, 49933, France
    Recruiting
  • GSK Investigational Site
    Brest, 29609, France
    Recruiting
  • GSK Investigational Site
    Nice, 06202, France
    Recruiting
  • GSK Investigational Site
    Nîmes, 30029, France
    Recruiting
  • GSK Investigational Site
    Paris, 75010, France
    Recruiting
  • GSK Investigational Site
    Poitiers, 86021, France
    Recruiting
  • GSK Investigational Site
    Essen, North Rhine-Westphalia 45147, Germany
    Recruiting
  • GSK Investigational Site
    Jena, Thuringia 07747, Germany
    Recruiting
  • GSK Investigational Site
    Lübeck, 23538, Germany
    Recruiting
  • GSK Investigational Site
    Mannheim, 68167, Germany
    Recruiting
  • GSK Investigational Site
    Milan, MI 20122, Italy
    Recruiting
  • GSK Investigational Site
    Bologna, 40138, Italy
    Recruiting
  • GSK Investigational Site
    Catania, 95123, Italy
    Recruiting
  • GSK Investigational Site
    Florence, 50134, Italy
    Recruiting
  • GSK Investigational Site
    Meldola FC, 47014, Italy
    Recruiting
  • GSK Investigational Site
    Roma, 161, Italy
    Recruiting
  • GSK Investigational Site
    Badalona, 08005, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, 8035, Spain
    Recruiting
  • GSK Investigational Site
    Las Palmas, 35020, Spain
    Recruiting
  • GSK Investigational Site
    Madrid, 28009, Spain
    Recruiting
  • GSK Investigational Site
    Madrid, 28034, Spain
    Recruiting
  • GSK Investigational Site
    Málaga, 29010, Spain
    Recruiting
  • GSK Investigational Site
    Valencia, 46026, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2028 → Jan 2029, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2024
First posted
Jul 24, 2024
StartActual
Feb 28, 2025
Primary completionEst.
Mar 16, 2027
CompletionEst.
Jan 31, 2029was Mar 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (2 Germany, 1 France, 1 Italy)
  • GSK Investigational Site · Lyon, France
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Jena, Germany
  • GSK Investigational Site · Milan, Italy
Show 4 removed
  • GSK Investigational Site · Lyon, France
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Jena, Germany
  • GSK Investigational Site · Milan, Italy
Nov 4, 2026
Primary completion
Mar 19, 2027→Mar 16, 2027
Nov 4, 2026
Study completion
Mar 17, 2028→Jan 31, 2029
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    4 sites added, 4 sites removed
    Show 4 added (2 Germany, 1 France, 1 Italy)
    • GSK Investigational Site · Lyon, France
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Jena, Germany
    • GSK Investigational Site · Milan, Italy
    Show 4 removed
    • GSK Investigational Site · Lyon, France
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Jena, Germany
    • GSK Investigational Site · Milan, Italy
    Primary completion Mar 19, 2027→Mar 16, 2027
    Study completion Mar 17, 2028→Jan 31, 2029
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06517875
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 24, 2024
Start date
Feb 28, 2025
Primary completion
Mar 16, 2027 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Momelotinib · Luspatercept

Start the discussion